Relmada Therapeutics Inc (NASDAQ:RLMD)’s traded shares stood at 1.1 million during the last session, with the company’s beta value hitting 0.61. At the close of trading, the stock’s price was $0.38, to imply an increase of 11.73% or $0.04 in intraday trading. The RLMD share’s 52-week high remains $7.22, putting it -1800.0% down since that peak but still an impressive 18.42% since price per share fell to its 52-week low of $0.31. The company has a valuation of $11.46M, with an average of 0.39 million shares in intraday trading volume over the past 10 days and average of 1.09 million shares over the past 3 months.
Analysts have given a consensus recommendation of Sell for Relmada Therapeutics Inc (RLMD), translating to a mean rating of 3.00. Of 1 analyst(s) looking at the stock, 1 analyst(s) give RLMD a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 0 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.
Relmada Therapeutics Inc (NASDAQ:RLMD) trade information
After registering a 11.73% upside in the last session, Relmada Therapeutics Inc (RLMD) has traded red over the past five days. The 5-day price performance for the stock is 4.17%, and -19.17% over 30 days. With these gigs, the year-to-date price performance is -26.92%. Short interest in Relmada Therapeutics Inc (NASDAQ:RLMD) saw shorts transact 1.26 million shares and set a 4.52 days time to cover.
The extremes give us $2 and $8 for target low and target high price respectively. As such, RLMD has been trading -2005.26% off suggested target high and -426.32% from its likely low.
Relmada Therapeutics Inc (RLMD) estimates and forecasts
Looking at statistics comparing Relmada Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Relmada Therapeutics Inc (RLMD) shares are -88.79% down over the last 6 months, with its year-to-date growth rate lower than industry average at 16.77% against 18.00%.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -2.94% for the past 5-year period. While 2025 is set for a 16.46% return in earnings, projections for the next 5 years are at 25.49% annually.
RLMD Dividends
Relmada Therapeutics Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Relmada Therapeutics Inc (NASDAQ:RLMD)’s Major holders
Relmada Therapeutics Inc insiders hold 8.04% of total outstanding shares, with institutional holders owning 46.06% of the shares at 50.09% float percentage. In total, 46.06% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 1.26 million shares (or 4.1706% of shares), all amounting to roughly $3.77 million.
The next major institution holding the largest number of shares is DEEP TRACK CAPITAL, LP with 1.23 million shares, or about 4.0979% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $3.7 million.
We also have Vanguard Total Stock Market Index Fund and Franklin Strategic Series-Franklin Biotechnology Discove as the top two Mutual Funds with the largest holdings of the Relmada Therapeutics Inc (RLMD) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 851.92 shares. This is just over 8.61% of the total shares, with a market valuation of $0.32 million. Data from the same date shows that the other fund manager holds a little less at 456.4, or 4.61% of the shares, all valued at about 0.17 million.
